Progress in Cytomegalovirus Vaccine Development

Author: Schleiss, Mark

Source: Herpes, Volume 12, Number 3, 2005 , pp. 66-75(10)

Publisher: Cambridge Medical Publications

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Cytomegalovirus (CMV) causes considerable morbidity and disability in infants who acquire the infection in utero. Despite potent antiviral therapies, CMV also continues to be a major cause of disease in immunocompromised patients. Vaccines for CMV, therefore, could provide protection against CMV disease in an array of high-risk patient populations. Although the correlates of vaccine-engendered immunity that limit CMV disease are not fully understood, there has been significant progress in elucidating some of the key immunological correlates of protection. The optimal CMV vaccine strategy may depend on the patient population being targeted for protection. This review provides an update on CMV vaccines that are currently in preclinical and clinical development, and outlines important, as yet unanswered, questions about the nature of protective immune responses that will be required of potential CMV immunization strategies. Such questions must be answered before an optimal vaccine, and vaccine use strategy, can be implemented in clinical practice.

Keywords: CYTOMEGALOVIRUS; CONGENITAL CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS VACCINES; HERPESVIRUS VACCINES; CYTOMEGALOVIRUS GLYCOPROTEIN B; TORCH INFECTIONS

Document Type: Research article

The full text article is available for purchase

$22.24 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A